Robert Wild to Estrogen Replacement Therapy
This is a "connection" page, showing publications Robert Wild has written about Estrogen Replacement Therapy.
Connection Strength
2.850
-
Hormone therapy formulation, dose, route of delivery, and risk of hypertension: findings from the Women's Health Initiative Observational Study (WHI-OS). Menopause. 2021 07 26; 28(10):1108-1116.
Score: 0.755
-
Insights from the Women's Health Initiative: individualizing risk assessment for hormone therapy decisions. Semin Reprod Med. 2014 Nov; 32(6):433-7.
Score: 0.472
-
The need for evidence-based medicine to be integrated into clinical practice: role of the North American Menopause Society. Menopause. 2009 May-Jun; 16(3):438-41.
Score: 0.323
-
Options for hormone therapy in women who have had a hysterectomy. Menopause. 2007 May-Jun; 14(3 Pt 2):592-7; quiz 598-9.
Score: 0.281
-
Soy protein has a greater effect on bone in postmenopausal women not on hormone replacement therapy, as evidenced by reducing bone resorption and urinary calcium excretion. J Clin Endocrinol Metab. 2003 Mar; 88(3):1048-54.
Score: 0.211
-
Cardiovascular disease (CVD) risk scores, age, or years since menopause to predict cardiovascular disease in the Women's Health Initiative. Menopause. 2021 05 03; 28(6):610-618.
Score: 0.186
-
Hormone replacement: effects on atherogenesis. Semin Reprod Endocrinol. 1996 Feb; 14(1):63-9.
Score: 0.129
-
Coronary heart disease events in the Women's Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women's Health Initiative randomized clinical trials. Menopause. 2013 Mar; 20(3):254-60.
Score: 0.105
-
Associations of postmenopausal hormone therapy with markers of hemostasis and inflammation and lipid profiles in diabetic and nondiabetic american Indian women: the strong heart study. J Womens Health (Larchmt). 2004 Mar; 13(2):155-63.
Score: 0.056
-
The association of hormone therapy with blood pressure control in postmenopausal women with hypertension: a secondary analysis of the Women's Health Initiative clinical trials. Menopause. 2023 01 01; 30(1):28-36.
Score: 0.051
-
The effect of estrogen use on levels of glucose and insulin and the risk of type 2 diabetes in american Indian postmenopausal women : the strong heart study. Diabetes Care. 2002 Mar; 25(3):500-4.
Score: 0.049
-
Estrogens, progestins, selective estrogen receptor modulators, and the arterial tree. Am J Obstet Gynecol. 2001 Apr; 184(5):1031-9.
Score: 0.046
-
The effects of hormone replacement therapy and raloxifene on C-reactive protein and homocysteine in healthy postmenopausal women: a randomized, controlled trial. J Clin Endocrinol Metab. 2000 Jan; 85(1):214-8.
Score: 0.042
-
Risk factors: assessment and preventive measures. Clin Obstet Gynecol. 1998 Dec; 41(4):966-75.
Score: 0.039
-
Effects of raloxifene on serum lipids and coagulation factors in healthy postmenopausal women. JAMA. 1998 May 13; 279(18):1445-51.
Score: 0.038
-
Effects of different hormone replacement regimens on postmenopausal women with abnormal lipid levels. Menopause Study Group. Climacteric. 1998 Mar; 1(1):26-32.
Score: 0.037
-
The gynecologist and cardiovascular disease: a window of opportunity for prevention. J Soc Gynecol Investig. 1994 Apr-Jun; 1(2):107-17.
Score: 0.028